Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market-Reference-Cited by-同舟云学术

Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market

Published:2021-10-01 Issue:10 Volume:181 Page:1405
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Levy Joseph¹,Chowdhury Zahra M.²,Socal Mariana P.¹,Trujillo Antonio J.²

Affiliation:

1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2781481/jamainternal_levy_2021_ld_210033_1632955217.33772.pdf

Reference6 articles.

1. Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018.;Hernandez;JAMA,2019

2. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition.;San-Juan-Rodriguez;JAMA Netw Open,2019

3. Atteberry? P, Bach? PB, Ohn? JA, Trusheim? MR. Biologics are natural monopolies (part 1): why biosimilars do not create effective competition. Health Affairs Blog. Accessed December 24, 2020. https://www.healthaffairs.org/do/10.1377/hblog20190405.396631/full/

4. Boehringer Ingelheim. FDA approves Basaglar (insulin glargine injection), a long-acting insulin treatment. News release. Accessed April 18, 2021. https://www.boehringer-ingelheim.us/press-release/fda-approves-basaglarr-insulin-glargine-injection-long-acting-insulin-treatment

5. Kakani? P, Chernew? M, Chandra? A. Rebates in the pharmaceutical industry: evidence from medicines sold in retail pharmacies in the US. National Bureau of Economic Research working paper 26846. March 2020. Accessed May 24, 2021. https://www.nber.org/papers/w26846

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019;Journal of Managed Care & Specialty Pharmacy;2024-01-01

2. Insulins and the Evolving Landscape of U.S. Prescription Drug Pricing;Annals of Internal Medicine;2023-09

3. Changes In Net Prices And Spending For Pharmaceuticals After The Introduction Of New Therapeutic Competition, 2011–19;Health Affairs;2023-08-01

4. Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States;Journal of Managed Care & Specialty Pharmacy;2023-07

5. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications;JAMA Health Forum;2023-06-09